Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| AstraZeneca settles Nexium liability litigations | 3 Oct 2023 |
| Total Voting Rights | 2 Oct 2023 |
| Dato-DXd improved PFS in breast cancer | 22 Sept 2023 |
| Alexion completes Pfizer gene therapy agreement | 20 Sept 2023 |
| Enhertu recommended in EU for HER2-mutant NSCLC | 15 Sept 2023 |
| Fasenra Phase III EGPA trial met primary endpoint | 11 Sept 2023 |
| Update on US review of Ultomiris for NMOSD | 6 Sept 2023 |
| Total Voting Rights | 1 Sept 2023 |
| Total Voting Rights | 1 Aug 2023 |
| Half-year Report | 28 Jul 2023 |
| Alexion enters gene therapy agreement with Pfizer | 28 Jul 2023 |
| Beyfortus approved in US for infant RSV prevention | 17 Jul 2023 |